Prevention of Perinatal Group B Streptococcal Infection: Management Strategies

Prevention of perinatal group B streptococcal infections.

Perinatal Group B Streptococcal Disease Prevention, Minnesota

In 2002, revised guidelines for preventing perinatal group B streptococcal disease were published. In 2002, all Minnesota providers surveyed reported using a prevention policy. Most screen vaginal and rectal specimens at 34-37 weeks of gestation. The use of screening-based methods has increased dramatically since 1998.

Prevention of neonatal group B streptococcal infection.

Neonatal group B streptococcal infection is the primary cause of neonatal morbidity related to infection. It can often be prevented by identifying and treating pregnant women who carry group B streptococci or who are at highest risk of transmitting the bacteria to newborns. Increasing evidence and expert opinion support intrapartum treatment of women at relatively high risk of delivering an inf...

Prevention of perinatal group B streptococcal disease: updated CDC guideline.

Group B streptococcus is the leading cause of early-onset neonatal sepsis in the United States. Universal screening is recommended for pregnant women at 35 to 37 weeks' gestation. The Centers for Disease Control and Prevention recently updated its guideline for the prevention of early-onset neonatal group B streptococcal disease. The new guideline contains six important changes. First, there is...

Prevention of Neonatal Group B Streptococcal Disease

which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Group B streptococci (GBS) are facultative anaerobic, gram-positive cocci that colonize the gastrointestinal and urogenital tracts of humans. GBS strains are serologically divided into 10 types (Ia, Ib, and II through IX) according to their capsula...